Crossmark

Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases

Crossref DOI link: https://doi.org/10.1007/s12094-024-03390-y

Published Online: 2024-02-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Manyi

Shao, Keda

Wang, Yanhua

Hao, Yue https://orcid.org/0000-0002-4725-6084
Song, Zhengbo
Funding

Funding for this research was provided by:

Medical Scientific Research Foundation of Zhejiang Province (No.2022KY653)
License Information

Text and Data Mining valid from 2024-02-16

Version of Record valid from 2024-02-16
More Information

Article History

Received: 27 November 2023

Accepted: 10 January 2024

First Online: 16 February 2024

Declarations

:

: All authors declare no conflict of interest.

: Approval of the study protocol was obtained from Zhejiang Cancer Hospital Institutional Review Board Committee (approval number: IRB-2023-268). Individual consent for this retrospective analysis was waived.

: Not applicable.

: Individual consent for analysis was waived.

Document is current

Any future updates will be listed below